JP2017171685A5 - - Google Patents

Download PDF

Info

Publication number
JP2017171685A5
JP2017171685A5 JP2017125081A JP2017125081A JP2017171685A5 JP 2017171685 A5 JP2017171685 A5 JP 2017171685A5 JP 2017125081 A JP2017125081 A JP 2017125081A JP 2017125081 A JP2017125081 A JP 2017125081A JP 2017171685 A5 JP2017171685 A5 JP 2017171685A5
Authority
JP
Japan
Prior art keywords
composition
solid tumor
composition according
peg
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017125081A
Other languages
English (en)
Japanese (ja)
Other versions
JP6440776B2 (ja
JP2017171685A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017171685A publication Critical patent/JP2017171685A/ja
Publication of JP2017171685A5 publication Critical patent/JP2017171685A5/ja
Application granted granted Critical
Publication of JP6440776B2 publication Critical patent/JP6440776B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017125081A 2006-09-28 2017-06-27 癌を処置するためのペグ化il−10の使用 Active JP6440776B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84832606P 2006-09-28 2006-09-28
US60/848,326 2006-09-28
US91560307P 2007-05-02 2007-05-02
US60/915,603 2007-05-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014250391A Division JP6169066B2 (ja) 2006-09-28 2014-12-10 癌を処置するためのペグ化il−10の使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018217411A Division JP6718494B2 (ja) 2006-09-28 2018-11-20 癌を処置するためのペグ化il−10の使用

Publications (3)

Publication Number Publication Date
JP2017171685A JP2017171685A (ja) 2017-09-28
JP2017171685A5 true JP2017171685A5 (enExample) 2018-01-18
JP6440776B2 JP6440776B2 (ja) 2018-12-19

Family

ID=39304838

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009530418A Active JP5105554B2 (ja) 2006-09-28 2007-09-27 癌を処置するためのペグ化il−10の使用
JP2012175219A Active JP5666523B2 (ja) 2006-09-28 2012-08-07 癌を処置するためのペグ化il−10の使用
JP2014250391A Active JP6169066B2 (ja) 2006-09-28 2014-12-10 癌を処置するためのペグ化il−10の使用
JP2017125081A Active JP6440776B2 (ja) 2006-09-28 2017-06-27 癌を処置するためのペグ化il−10の使用
JP2018217411A Active JP6718494B2 (ja) 2006-09-28 2018-11-20 癌を処置するためのペグ化il−10の使用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2009530418A Active JP5105554B2 (ja) 2006-09-28 2007-09-27 癌を処置するためのペグ化il−10の使用
JP2012175219A Active JP5666523B2 (ja) 2006-09-28 2012-08-07 癌を処置するためのペグ化il−10の使用
JP2014250391A Active JP6169066B2 (ja) 2006-09-28 2014-12-10 癌を処置するためのペグ化il−10の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018217411A Active JP6718494B2 (ja) 2006-09-28 2018-11-20 癌を処置するためのペグ化il−10の使用

Country Status (12)

Country Link
US (6) US20080081031A1 (enExample)
EP (3) EP2066336B1 (enExample)
JP (5) JP5105554B2 (enExample)
CN (1) CN101631560B (enExample)
AU (1) AU2007314501B2 (enExample)
BR (1) BRPI0719446A2 (enExample)
CA (1) CA2664304C (enExample)
ES (1) ES2606034T3 (enExample)
MX (1) MX2009003362A (enExample)
NO (1) NO346530B1 (enExample)
NZ (1) NZ597098A (enExample)
WO (1) WO2008054585A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
NZ597098A (en) * 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
JP5888980B2 (ja) 2008-12-17 2016-03-22 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. モノ−およびジ−pegil10の製造および用途
KR20130001279A (ko) 2010-04-01 2013-01-03 온코레나 에이비 신장세포 암종의 향상된 치료
TW201311255A (zh) * 2011-04-27 2013-03-16 Univ Northshore Healthsystem 組成物和方法
WO2013130913A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
WO2014172392A1 (en) * 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2016005915A (es) * 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
WO2015108785A1 (en) * 2014-01-15 2015-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
JP7053453B2 (ja) * 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン10の使用方法
EP3400067A4 (en) * 2016-01-05 2019-08-21 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
EP3402512A4 (en) 2016-01-11 2019-09-25 Armo Biosciences, Inc. INTERLEUKIN-10 IN THE PREPARATION OF ANTIGEN-SPECIFIC CD8 + T CELLS AND METHOD FOR THE USE THEREOF
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
JP7177439B2 (ja) 2016-05-10 2022-11-24 国立大学法人 東京医科歯科大学 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
CA3082006A1 (en) * 2017-11-09 2019-05-16 National University Corporation Tokyo Medical And Dental University Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnosticmethod
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
CN112533629A (zh) * 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
US20230023414A1 (en) 2018-11-19 2023-01-26 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11084857B2 (en) 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
BR102019007044A2 (pt) 2019-04-05 2021-12-28 Universidade Federal de Uberlândia Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4274616A2 (en) 2021-01-11 2023-11-15 Synthekine, Inc. Compositions and methods related to receptor pairing
US20240190934A1 (en) * 2022-11-28 2024-06-13 Elixiron Immunotherapeutics (hong Kong) Limited Engineered interleukin-10 and fusion proteins thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5032396A (en) 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0567586T3 (da) 1991-01-16 1995-12-04 Schering Corp Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
HU218598B (hu) 1991-01-16 2000-10-28 Schering Corp. Eljárás interleukin-10-et tartalmazó, tumorok kezelésére szolgáló gyógyszerkészítmények előállítására
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
HU220103B (hu) * 1992-08-20 2001-10-28 Schering-Plough Corp. IL-10 új alkalmazása
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
WO1994022473A1 (en) 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
SK8396A3 (en) 1993-07-26 1997-03-05 Schering Corp Antagonists and agonists of human interleukin-10
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0740552A1 (en) * 1994-01-20 1996-11-06 Schering Corporation Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5866134A (en) * 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
HUP9903546A3 (en) * 1995-07-14 2002-02-28 Schering Corp Treatment of acute leukemia with interleukin-10
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5759859A (en) 1996-07-15 1998-06-02 United States Of America As Represented By The Secretary Of The Army Sensor and method for detecting trace underground energetic materials
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6362276B1 (en) 1998-01-07 2002-03-26 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
AU5827000A (en) * 1999-07-16 2001-02-05 Maria Teresa Bejarano Viral il-10 uses
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗-cd20在b细胞淋巴瘤治疗中的联合应用
US7052686B2 (en) * 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002307497A1 (en) 2001-04-23 2002-11-05 The Regents Of The University Of California Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
AU2003263552A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
AU2003280315A1 (en) 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
DK1565183T3 (da) 2002-11-29 2008-12-01 Maria Grazia Roncarolo Rapamycin og IL-10 til behandling af autoimmune sygdomme
TWI364295B (en) 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EP2261244A3 (en) 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005033307A1 (ja) 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
DK1699822T3 (da) 2003-12-30 2008-08-04 Merck Patent Gmbh IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
WO2005084712A2 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
WO2006061219A2 (en) 2004-12-09 2006-06-15 Merck Patent Gmbh Il-7 variants with reduced immunogenicity
WO2006094530A1 (en) 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2006119170A2 (en) * 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
JP4992025B2 (ja) 2005-05-31 2012-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 変異体il−10
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
US7939056B2 (en) * 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
NZ597098A (en) * 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
WO2008041953A2 (en) 2006-10-05 2008-04-10 Agency For Science, Technology And Research Dengue diagnosis and treatment
JP5220025B2 (ja) 2006-12-04 2013-06-26 プロメディオール, インコーポレイテッド 線維症疾患を処置するための併用療法
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR IMPROVING INFLAMMATION OF SN, PSYCHOSIS, DELI, PTSD OR PTSD
US9170262B2 (en) 2010-06-16 2015-10-27 Abbvie, Inc. Comparison of protein samples
US8759617B2 (en) 2010-09-21 2014-06-24 National Institute Of Agrobiological Sciences Method for extraction and purification of recombinant proteins from transgenic plants
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
KR20170125839A (ko) 2015-03-11 2017-11-15 넥타르 테라퓨틱스 Il-7 부분 및 중합체의 접합체

Similar Documents

Publication Publication Date Title
JP2017171685A5 (enExample)
Araste et al. Peptide-based targeted therapeutics: Focus on cancer treatment
Dos Santos et al. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents
JP2015514109A5 (enExample)
ES2703826T3 (es) Inmunoterapia con IL-12 destinada al cáncer
ES2732005T3 (es) Una combinación de tetrahidrocannabinol y cannabidiol para uso para aumentar la radiosensibilidad en el tratamiento de un tumor cerebral
JP2015505843A5 (enExample)
RU2016132759A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
JP2017521486A5 (enExample)
Wang et al. Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force
JP2016528162A5 (enExample)
JP2015512398A5 (enExample)
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
JP2016530233A5 (enExample)
Wang et al. Systemic administration of attenuated Salmonella typhimurium in combination with interleukin-21 for cancer therapy
WO2020018996A3 (en) Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
Engel et al. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins
JP2009510165A5 (enExample)
Chou et al. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment
JP2008523067A5 (enExample)
Huang et al. Safety of lienal polypeptide injection combined with chemotherapy in treating patients with advanced cancer
JP2017515806A5 (enExample)
ES2845724T3 (es) Micobacteria recombinante como agente inmunoterapéutico para el tratamiento de cáncer
Hegde et al. To market, to market—2008